WHAT IS ANADROL(OXYMETHOLONE)？
(Oxymetholone) is an oral anabolic steroid derived from dihydrotestosterone. More specifically, it is simply a methyldihydrotestosterone formed by the addition of a 2-hydroxymethylene group. This produces a similar steroid, which is significantly different in activity compared to methenolone, but it is difficult to compare between the two. For beginners, Anadrol is a very effective anabolic hormone. Since these molecules are not very stable in the high enzyme (3-alpha hydroxysteroid dehydrogenase) environment of muscle tissue, both dihydrotestosterone and methenolone are very weak. Oxygen free radicals remain highly active here, and as reported in standard animal assays, they have higher anabolic activity than testosterone or methyltestosterone. Such assays indicate that Anadrol is also very low in androgenicity. Many people think that Anadrol is the most powerful steroid on the market. A newcomer using steroids may get 20 to 30 pounds of weight, and usually achieve this effect within 6 weeks of use. This steroid will cause the body to store a large amount of water, so a large part of this increased body weight will be water. This usually has little effect on the user, and they feel great and strong when taking Anadrol. Although the smooth appearance obtained by water storage is usually not attractive, it can greatly increase the size and strength. The muscles are fuller, contractile, and provide a degree of protection from additional water and connective tissue. This will gain more flexibility and will hopefully reduce the chance of serious weight loss. However, it should be noted that very fast mass gains can also put too much stress on connective tissue. Tears of the pectoral and biceps tissues are often associated with heavy weight lifting.
History: Anadrol (Oxymetholone) first appeared in 1959. The drug was prescribed in the United States in the early 1960s and sold under the brand names Anadrol-50 (Syntex) and Androyd (Parke Davis & Co.) Syntex became an agent and held patents until many years later. Expiration. The drug was originally approved for use in conditions requiring anabolic effects. Indications include ageing weakness, chronic underweight condition, pre-operative and postoperative maintenance of lean body mass, infection recovery, gastrointestinal disease, Osteoporosis and general catabolic conditions. The recommended dose for this use is usually 2.5 mg once daily three times a day. The drug is initially given as a 2.5 mg, 5 mg or 10 mg tablet. Although the drug has many potentials Therapeutic use and strong anabolic activity, but the FDA quickly narrowed the use of Anadrol. By the mid-1970s, the drug was approved by the FDA for treatment only with red blood cell (RBC) deficiency. Anemia. It is true that stimulating erythropoiesis is characteristic of almost all anabolic steroids, and they are used as a group to increase red blood cell concentration. However, in this regard, Anadrol seems to When reliable; can increase erythropoietin levels up to 5-fold. This has led to the adoption of this relatively new medical use, as well as the use of newer Anadrol-50 products to prepare higher (50mg) doses. This has a greater impact on RBC counts. However, the Park Davis project will not be raised to higher doses and has stopped. In recent years, there have been some new treatments for anemia, especially It uses Epogen (recombinant erythropoietin) and related erythropoietin peptides. These drugs directly mimic the body's natural erythropoietin, thus providing a more concentrated treatment and producing fewer males. Hormone side effects. Although Anadrol was once considered an effective drug, sales were declining. Low profit finally caused Syntex to stop producing American Anadrol 50 in 1993, probably at the same time they decided to give up some foreign countries. Some of the projects. Anadrol in Switzerland and Austria was initially abandoned; followed by Oxitosona in the squad. In the mid-1990s, many athletes worried that Anadrol became less and less. In July 1997, Syntex will be in the US The ownership of Anadrol-50 in Canada and Mexico was sold to Unimed Pharmaceuticals. In 1998, Unadrol-50 was reintroduced into the US market, where the audience was HIV/AIDS patients. HIV patients are usually anaemic Often caused by the disease itself, opportunistic infections or antiretroviral drugs used to treat the disease. Anemia in HIV patients is usually attributed to impaired production of red blood cells in the medullary pulp, and FDA approved the use of hydroxyprogesterone. In addition, Anadrol showed great hope in the study of HIV prevention. Unadel is about to start phase II/III trial of HIV syndrome with Anadrol and continues to study chronic obstructive pulmonary disease and lipodystrophy (characterized by selective loss of body fat, insulin resistance, diabetes, high gan Oil triester levels and fatty liver). In April 2006, Solvay Pharmaceuticals (the parent company of Unimed) sold the rights of Anadrol-50 to Alaven Pharmaceutical, LLC. Alaven continues to sell the drug in the United States, but is not sure about using Anadrol for other purposes. Currently the only FDA approval is for the treatment of erythrocyte anemia. Syntex seems to have seceded from the global Anadrol market and stopped producing products or transferring licenses to other companies as much as possible. Anadrol can still be used outside the US, but it is mainly sold to smaller and less regulated markets. Specifications available: Anadrol is available in certain human drug markets. Ingredients and dosages may vary by country and manufacturer. Most brands contain 50 mg of steroids per tablet.